Aligos Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Aligos Therapeutics

03/05/2023 03:05

* Aligos Therapeutics Inc  ALGS.OQ   ALGS.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 4. 
    * 
    * ​Refinitiv's mean analyst estimate for Aligos Therapeutics
Inc
is for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3​, above​ its last closing price of $1.21.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.46       -0.47      -0.51     Missed  -8.1
 Sep. 30 2022  -0.56       -0.58      -0.44     Beat    24.1
 Jun. 30 2022  -0.62       -0.67      -0.47     Beat    29.5​
 Mar. 31 2022  -0.74       -0.73      -0.84     Missed  -15.5
 ​​Dec.        -0.88       -0.83      -0.89     Missed  -7.5
 31 2021                                                
 Sep. 30 2021  -0.81       -0.81      -0.78     Beat    4.2​
 Jun. 30 2021  -0.81       -0.81      -0.79     Beat    2.1
 Mar. 31 2021  -0.90       -0.90      -0.74     Beat    17.8
 This summary was machine generated May 3 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated